BR112015026685A2 - agente de diminuição de ácido úrico - Google Patents

agente de diminuição de ácido úrico

Info

Publication number
BR112015026685A2
BR112015026685A2 BR112015026685A BR112015026685A BR112015026685A2 BR 112015026685 A2 BR112015026685 A2 BR 112015026685A2 BR 112015026685 A BR112015026685 A BR 112015026685A BR 112015026685 A BR112015026685 A BR 112015026685A BR 112015026685 A2 BR112015026685 A2 BR 112015026685A2
Authority
BR
Brazil
Prior art keywords
tyrosine
uric acid
lowering agent
acid lowering
cyclothyrosyl
Prior art date
Application number
BR112015026685A
Other languages
English (en)
Inventor
Watanabe Hiroshi
Fukizawa Shinya
Suzuki Toshihide
Beppu Yoshinori
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of BR112015026685A2 publication Critical patent/BR112015026685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

resumo patente de invenção: "agente de diminuição de ácido úrico". trata-se de um agente de diminuição de ácido úrico que contém, como um ingrediente ativo, um dipeptídeo cíclico contendo tirosina selecionado a partir de um grupo que consiste em ciclotriptofaniltirosina, cicloseriltirosina, cicloproliltirosina, ciclotirosilglicina, ciclotirosiltirosina, ciclofenilalaniltirosina, cicloleuciltirosina, ciclolisiltirosina, ciclohistidiltirosina, cicloalaniltirosina, cicloglutamiltirosina, ciclovaliltirosina, cicloisoleuciltirosina, ciclotreoniltirosina, cicloaspartiltirosina, cicloasparaginiltirosina, cicloglutaminiltirosina, cicloarginiltirosina, ciclometioniltirosina e ciclotirosilcisteína ou um sal dos mesmos. o agente de diminuição de ácido úrico da presente invenção tem uma excelente ação de diminuição de um nível de ácido úrico, e o agente de diminuição de ácido úrico é útil, por exemplo, na prevenção ou no tratamento de hiperuricemia, gota ou similar. 1/1
BR112015026685A 2014-06-20 2014-06-20 agente de diminuição de ácido úrico BR112015026685A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/066424 WO2015194034A1 (ja) 2014-06-20 2014-06-20 尿酸値低下剤

Publications (1)

Publication Number Publication Date
BR112015026685A2 true BR112015026685A2 (pt) 2017-07-25

Family

ID=52823346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026685A BR112015026685A2 (pt) 2014-06-20 2014-06-20 agente de diminuição de ácido úrico

Country Status (13)

Country Link
US (1) US9650415B2 (pt)
EP (1) EP3159005A1 (pt)
JP (1) JP5690028B1 (pt)
KR (1) KR20160022292A (pt)
CN (1) CN105407907A (pt)
AU (1) AU2014386720B2 (pt)
BR (1) BR112015026685A2 (pt)
CA (1) CA2904493A1 (pt)
HK (1) HK1215797A1 (pt)
MX (1) MX2015015162A (pt)
SG (1) SG11201507823RA (pt)
TW (1) TWI564018B (pt)
WO (1) WO2015194034A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014200000A1 (ja) 2013-06-10 2014-12-18 サントリーホールディングス株式会社 ジケトピペラジンを含有する植物エキス及びその製造方法
JP6772133B2 (ja) * 2015-07-02 2020-10-21 サントリーホールディングス株式会社 Ｇｌｐ−２分泌促進用組成物
WO2017002906A1 (ja) * 2015-07-02 2017-01-05 サントリーホールディングス株式会社 アルコール吸収抑制用組成物
JP6669750B2 (ja) * 2015-07-16 2020-03-18 サントリーホールディングス株式会社 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物
WO2017014120A1 (ja) * 2015-07-17 2017-01-26 サントリーホールディングス株式会社 Ｔｒｐｖ１刺激用組成物
SG10201912392SA (en) * 2015-07-27 2020-02-27 Suntory Holdings Ltd Composition containing cyclic dipeptide and sweetening agent
JP6719475B2 (ja) * 2015-09-04 2020-07-08 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
CN109562110A (zh) 2016-05-26 2019-04-02 株式会社日本阿明诺化学 睡眠改善剂
JP2019011303A (ja) * 2017-07-03 2019-01-24 サントリーホールディングス株式会社 環状ジペプチドの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
PT1311269E (pt) * 2000-08-04 2012-05-10 Dmi Biosciences Inc Método de utilização de dicetopiperazinas e composição que contém as mesmas
ES2297142T3 (es) 2002-03-28 2008-05-01 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina y su uso como antagonistas del receptor de dopamina para el tratamiento de trastornos psicoticos.
EP2537524B1 (en) * 2003-05-15 2016-07-06 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
JP2006111541A (ja) 2004-10-12 2006-04-27 Toyo Shinyaku:Kk 葛花処理物を含有する経口用肌質改善剤
EP2088143A1 (en) * 2008-01-24 2009-08-12 Commissariat A L'energie Atomique Novel inhibitors of mycobacterium tuberculosis complex cytochrome P450 CYP121
JP5058379B2 (ja) 2009-12-25 2012-10-24 サントリーホールディングス株式会社 学習意欲改善剤
JP2013053115A (ja) * 2011-09-06 2013-03-21 Josho Gakuen α環状ジペプチドの製造方法
WO2014200000A1 (ja) * 2013-06-10 2014-12-18 サントリーホールディングス株式会社 ジケトピペラジンを含有する植物エキス及びその製造方法

Also Published As

Publication number Publication date
AU2014386720B2 (en) 2016-07-21
TWI564018B (zh) 2017-01-01
CN105407907A (zh) 2016-03-16
KR20160022292A (ko) 2016-02-29
JPWO2015194034A1 (ja) 2017-04-20
US9650415B2 (en) 2017-05-16
CA2904493A1 (en) 2015-12-20
MX2015015162A (es) 2016-03-15
AU2014386720A1 (en) 2016-01-21
US20160159858A1 (en) 2016-06-09
JP5690028B1 (ja) 2015-03-25
EP3159005A1 (en) 2017-04-26
TW201600103A (zh) 2016-01-01
HK1215797A1 (zh) 2016-09-15
SG11201507823RA (en) 2016-01-28
WO2015194034A1 (ja) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112015026685A2 (pt) agente de diminuição de ácido úrico
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
NZ733174A (en) Quinazoline derivatives used to treat hiv
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
WO2017066121A9 (en) Controlled and precise treatment of cardiac tissues
EA201791467A1 (ru) Водный офтальмологический раствор
BR112019011769A2 (pt) composição de anticorpo anti-c5 aquosa estável
BR112017003186A2 (pt) composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
AU2015275507A8 (en) Cyclic dipeptide-containing composition
TW201625535A (en) Inhibitors of histone demethylases
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112017004925A2 (pt) composição e método

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]